We are a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain. We filed two Investigational New Drug, or IND, applications with the U.S. Food and Drug Administration, or FDA, in the first quarter of 2019 for our lead asset candidate, IkT-148009. One IND is for the treatment of Parkinson’s Disease, while the second is for treatment of gastrointestinal, or GI, complications that arise as early symptoms of PD in patients. 

(Note: This IPO was upsized at pricing to 1.8 million shares, up from its previously trimmed size of 1.36 million shares, and the IPO was priced at $10, the low end of its $10-to-$12 range. This IPO was refiled on Dec. 4, 2020, following its postponement in November. In an S-1/A filing dated Nov. 2, 2020, the IPO’s size was cut to 1.36 million shares, down from 2.27 million shares in a previous filing. The price range remained the same at $10 to $12.)